Explanation from the board of directors of Jiangsu Aidea Pharmaceutical regarding the company's major asset restructuring, which does not constitute a re-listing as defined in Article 13 of the Measures for the Administration of Major Asset Restructuring of Listed Companies.

SZSI · Jun 26

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

艾迪药业董事会关于公司本次重大资产重组不构成《上市公司重大资产重组管理办法》第十三条规定的重组上市的说明

Explanation from the board of directors of Jiangsu Aidea Pharmaceutical regarding the company's major asset restructuring, which does not constitute a re-listing as defined in Article 13 of the Measures for the Administration of Major Asset Restructuring of Listed Companies.

Risk Disclaimer

Statement